VR/AR Technology for Healthcare Market to Add US$11.31 Billion by 2033 as Surgical Guidance, Rehabilitation, Pain Care and Clinician Training Move Immersive Tools Into Clinical Workflows

NEW YORK, May 13, 2026 - The global VR/AR Technology for Healthcare Market reached US$5.03 billion in 2025 and is expected to reach US$16.34 billion by 2033, growing at a CAGR of 15.8% during 2026-2033, according to the supplied market model. The forecast represents an additional US$11.31 billion in annual market value by 2033, supported by clinical demand for surgical visualization, provider training, rehabilitation, pain management, remote care, diagnostics support, and workflow efficiency.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/vr-and-ar-technology-for-healthcare-market?kailas

The market's strongest growth story is not "immersive healthcare" as a future concept. It is the practical use of VR and AR to improve care delivery in moments where clinicians need better visualization, patients need more accessible therapy, and health systems need scalable training. In surgery, AR can help clinicians understand complex anatomy and guide procedures with richer visual context. In rehabilitation, VR can support repeatable exercises, patient engagement, and remote monitoring. In pain care, prescription VR therapy is already showing how immersive treatment can move into the home. In medical education, simulation gives clinicians more opportunities to practice before treating patients.

Regulatory relevance is also becoming clearer. The U.S. FDA maintains a public list of medical devices that incorporate augmented reality and virtual reality, covering legally marketed devices cleared through 510(k), De Novo, or PMA pathways. The agency says it encourages the development of innovative, safe, and effective AR/VR medical devices, signaling that the category is now part of mainstream digital health oversight rather than a peripheral technology discussion.

Recent Developments Reshaping the Market

1. FDA's AR/VR device list strengthened regulatory visibility. The FDA's Digital Health Center of Excellence developed its AR/VR medical device list to increase transparency and access to information on legally marketed products. For buyers, this matters because hospitals and specialty clinics increasingly need evidence, classification clarity, training requirements, and safety information before deploying immersive technologies in clinical settings.

2. VR pain therapy is moving into home-based care. AppliedVR's RelieVRx is described by the company as the first FDA-authorized prescription VR medical device for chronic lower back pain. Its product materials cite an eight-week, in-home behavioral skills-based program and published evidence reporting durable pain reductions up to 24 months after treatment. This is one of the strongest examples of VR shifting from hospital demonstration to patient-managed therapy.

3. Image-guided therapy is using spatial visualization to reduce procedural burden. Philips expanded commercial availability of LumiGuide 3D Device Guidance across Europe and the United States in 2025. Philips describes LumiGuide as a real-time AI-enabled, light-based 3D navigation solution for image-guided therapy that visualizes devices in 3D using light rather than continuous X-ray, supporting navigation in complex endovascular procedures.

4. Medical training is becoming a high-value implementation route. Fundamental XR positions its haptic VR simulation platform around surgical readiness and complex procedure training, while peer-reviewed literature continues to evaluate haptics in virtual surgical simulation as a way to improve personalized learning and procedural preparation. The strongest adoption case is not replacing supervised clinical education, but expanding safe rehearsal and competency development before patient contact.

5. AR is being used for clinical workflow education and equipment onboarding. Siemens Healthineers describes its ExpertGuidance service as an augmented reality experience for equipment onboarding and clinical workflow knowledge, built around the challenge that clinical workflows and medical equipment are becoming more complex. This reflects a practical implementation path: AR does not need to start inside the operating room; it can first reduce training burden and improve workflow knowledge.

Market Segmentation: Clinical Revenue Pools and Future Opportunity

By component, hardware remains the largest 2025 revenue pool because headsets, AR displays, haptic devices, imaging interfaces, sensors, simulation systems, and computing infrastructure are still required for deployment. Analyst allocation places hardware at approximately 43% of 2025 revenue, equal to about US$2.16 billion. However, hardware share is expected to moderate as platforms mature and as software, content, integration, analytics, and services capture more value.

Software is expected to become the fastest-scaling component segment. It is estimated at around 37% of 2025 revenue, or about US$1.86 billion, with potential to exceed US$6.7 billion by 2033 if it reaches about 41% of market value. This includes surgical planning tools, simulation modules, rehabilitation programs, VR exposure therapy software, pain-management programs, remote-care platforms, and analytics. The reason software is becoming more attractive is that hospitals need validated clinical workflows, not one-off devices.

By technology, augmented reality is expected to lead in surgical guidance, image-guided procedures, diagnostics support, and clinician workflow. AR is estimated at about 54% of 2025 revenue, or roughly US$2.72 billion, because it can layer information into real-world clinical environments. AR's highest-value uses include preoperative planning, anatomy visualization, procedural guidance, equipment onboarding, and clinician training.

Virtual reality is expected to expand strongly in medical education, rehabilitation, pain care, behavioral therapy, and remote therapeutic applications. VR is estimated at around 46% of 2025 revenue, or about US$2.31 billion, with faster adoption in settings where a controlled digital environment improves repeatability and patient engagement. VR exposure therapy, physical therapy, stroke rehabilitation, chronic pain programs, and simulation training are among the most credible growth areas.

By application, training and medical education are expected to remain a major revenue pool because workforce shortages, procedural complexity, and patient-safety requirements are pushing hospitals to improve clinician readiness. This segment is estimated at approximately 26% of 2025 revenue, or US$1.31 billion. Surgical applications are estimated at around 24%, or US$1.21 billion, with future growth tied to image-guided therapy, surgical planning, and specialty procedure support. Physical therapy and rehabilitation are estimated at nearly 18%, or US$0.91 billion, reflecting growing demand for guided therapy, home-based recovery, and patient engagement tools.

Regional Analysis: United States and Europe

The United States is expected to remain the largest and most commercially important market. Analyst estimates place the U.S. at roughly 38%-41% of global 2025 revenue, equal to about US$1.91-2.06 billion, with potential to exceed US$6.4 billion by 2033. The U.S. market benefits from FDA visibility, advanced hospital systems, digital therapeutics adoption, large orthopedic and surgical volumes, chronic pain demand, and strong venture-backed medtech activity.

The most attractive U.S. use cases are those tied to measurable outcomes: reducing surgical planning time, improving training consistency, supporting chronic pain without opioid escalation, improving therapy adherence, and extending rehabilitation outside the clinic. Hospitals and specialty clinics are not buying VR and AR because they are immersive; they are buying them when they reduce friction in care delivery or help clinicians make better decisions.

Europe is also gaining traction, especially in image-guided therapy, rehabilitation, training, and hospital workflow modernization. Philips' expansion of LumiGuide across Europe and the United States shows that European adoption is tied closely to procedural innovation, radiation management, and complex endovascular care. Europe's opportunity is also supported by centralized health systems that can scale proven technologies across hospital networks once clinical and cost evidence is strong enough.

Detailed Company Profiles
Koninklijke Philips N.V.
Philips is positioned strongly in AR-enabled healthcare because of its image-guided therapy footprint. Its LumiGuide 3D Device Guidance solution is commercially available across Europe and the United States and integrates with Philips' Azurion image-guided therapy platform. Philips states the technology uses light rather than continuous X-ray to visualize devices in 3D, full color, and real time, which directly addresses procedural navigation and radiation-exposure concerns in complex vascular interventions.

For the market, Philips represents the clinical-grade AR pathway: not consumer-style headsets, but workflow-integrated visualization in procedure rooms. This is important because hospitals are more likely to adopt immersive tools when they connect to existing imaging platforms, staff workflows, reimbursement logic, and procedural safety priorities.

Siemens Healthineers
Siemens Healthineers is relevant to the market through extended reality for training, visualization, and workflow support. The company describes use cases where hospitals, physicians, medical staff, university medical schools, and students benefit from virtual and augmented reality training scenarios. Its ExpertGuidance material also positions AR as a tool for equipment onboarding and clinical workflow knowledge, addressing the complexity of modern medical equipment and the need for continuous education.

This places Siemens Healthineers in the provider-workflow segment. The company's opportunity is not limited to immersive simulation; it sits in the broader push to help hospitals train staff, operate complex equipment, and reduce workflow learning curves.

CAE Inc.
CAE is an important simulation and training company with healthcare relevance through clinical education and patient-safety workflows. CAE's FY25 financial report positions the company as a global training and simulation leader. In healthcare, simulation platforms are closely aligned with VR and AR adoption because hospitals, nursing programs, emergency teams, and procedural specialties need safe environments for skills practice before clinical execution.

CAE's relevance is strongest in training infrastructure. Healthcare systems facing staffing shortages and rising procedure complexity need scalable ways to standardize learning. VR and AR can strengthen that model by giving learners repeated practice, scenario variation, and competency measurement.

Fundamental Surgery / Fundamental XR
Fundamental XR is positioned around immersive surgical simulation and haptic training. The company describes its platform as supporting surgical readiness, including use cases for complex ophthalmic procedures. Its market relevance is strengthened by the broader clinical discussion around haptics and simulation, where research indicates potential value for efficient and personalized surgical learning while also emphasizing the need for validation and standardized protocols.

Fundamental XR's opportunity is tied to procedure adoption. As new surgical devices, biologics, and advanced procedures enter care settings, manufacturers and hospitals need better ways to train clinicians consistently and safely. Haptic VR simulation can become a bridge between product launch, clinician confidence, and procedural quality.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=vr-and-ar-technology-for-healthcare-market?kailas

Analyst Views

The VR/AR technology for healthcare market is entering a clinical implementation phase. The strongest lead-generation message is not that healthcare is becoming immersive. It is that VR and AR can help solve specific care problems: better surgical visualization, safer training, more consistent rehabilitation, non-opioid pain support, remote therapy access, clinician onboarding, and patient understanding.

The most attractive buyers are hospitals and specialty clinics, surgical diagnostic centers, medical-device companies, rehabilitation providers, digital therapeutics developers, and training institutions. These buyers will evaluate immersive technology through evidence, workflow fit, regulatory pathway, patient safety, integration burden, and reimbursement potential.

Key players shaping the market include F. Hoffmann-La Roche Ltd, CAE Inc., EON Reality, Inc., InfiVR Solutions, Vection Technologies, Siemens Healthcare S.A.E., Fundamental Surgery, Koninklijke Philips N.V., Novac Technology Solutions, and Softeq Development Corp., among others.

The projected rise from US$5.03 billion in 2025 to US$16.34 billion by 2033 should be read as a clinical workflow opportunity, not a headset trend. The winners will be companies that can demonstrate patient benefit, provider usability, regulatory clarity, evidence quality, and implementation value. In healthcare, immersive technology will scale when it helps clinicians deliver better care and helps patients access therapy more effectively.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.